Alkem Laboratories Block Deal: Promoter Group Member, Jayanti Sinha to Sell 1.42% Stake

On June 4, 2025, Alkem Laboratories shares fell ~2%, reaching a day low of ₹4873.60 at 10:04 AM after opening at ₹4,948.00 on BSE. The fall in Alkem Laboratories shares follows a new circulating that Jayanti Sinha, a member of the promoter group of the company, is reportedly planning to offload a 1.42% stake through a block deal, according to CNBC-TV18.

The total deal size is expected to be around ₹825 crore, based on information from individuals familiar with the development.

Block Deal Details

The floor price for the transaction has been set at ₹4,850 per share, which represents a discount of roughly 3% compared to the current market price of Alkem Laboratories' stock. Axis Capital will serve as the broker for the deal, facilitating the stake sale on behalf of the promoter.

Alkem Laboratories Reports Stable Financial Performance in FY25

For FY25, Alkem Laboratories posted total revenue from operations of ₹1,29,645 million, reflecting a modest 2.3% year-on-year (YoY) growth. Domestic operations performed well, generating ₹89,837 million in revenue, up 6.5% YoY. However, international sales declined by 4.5%, totaling ₹38,210 million.

The company’s EBITDA stood at ₹25,122 million, an increase of 11.9% compared to the previous year. This translated to an improved EBITDA margin of 19.4%, up from 17.7% in FY24. R&D expenditure rose to ₹5,620 million, or 4.3% of total operating revenue, compared to ₹5,229 million (4.1%) in the prior year.

Also Read: Best Pharma Stocks in June 2025: Sun Pharma, Torrent Pharma, and More – Based on 5-Year CAGR

Profit before tax (excluding exceptional items) climbed 17.8% YoY to ₹25,270 million, while net profit after minority interest rose by 20.6% to ₹21,655 million. As of March 31, 2025, the company held cash and cash equivalents amounting to ₹46.2 billion, highlighting a strong liquidity position.

According to IQVIA (SSA) data, Alkem Laboratories reported a 6.8% YoY growth in FY25, slightly lagging behind the Indian Pharmaceutical Market (IPM), which grew by 7.7%. However, in the acute therapy segment, the company outperformed the broader market with a growth rate of 6.9%, surpassing the IPM’s performance by 30 basis points.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.